Abstract
Large cell neuroendocrine cancer of lung (LCNEC) is a rare type of lung cancer and data regarding the effect of immune checkpoint inhibitors (ICI) on LCNEC is limited. This retrospective study aims to investigate the efficacy of adding ICI to standard chemotherapy (CT) in the treatment of patients with stage IV LCNEC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
